It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Biotech
Forward Pharma developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications, primarily multiple sclerosis. Forward Pharma was acquired by Biogen for $1.25 billion in 2017.
Location
Denmark
History
Acquired by Biogen for $1.25 billion in 2017
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
